<DOC>
	<DOCNO>NCT01240525</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy , fludarabine melphalan , donor stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Giving infusion donor 's T cell ( donor lymphocyte infusion ) treat laboratory transplant may help increase effect . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving alemtuzumab transplant cyclosporine transplant , may stop happen . PURPOSE : This randomized phase II trial study donor lymphocyte infusion stem cell transplant prevent cancer relapse cancer progression patient follicular lymphoma , small lymphocytic non-Hodgkin lymphoma , chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Donor Lymphocyte Infusion After Stem Cell Transplant Treating Patients With Haematological Cancers</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate effect prophylactic transfer donor CD4 cell T-cell deplete reduced-intensity HLA-identical sibling transplantation upon risk relapse progression patient haematological cancer ( e.g . NHL , HL , CLL/PLL , PCM , AML , ALL , MDS CMML depend disease status ) . Secondary - To evaluate effect prophylactic transfer donor CD4 cell upon risk graft-versus-host disease ( GvHD ) patient . - To evaluate effect prophylactic transfer donor CD4 cell upon rate conversion full donor chimerism peripheral blood patient . - To determine effect prophylactic transfer donor CD4 cell upon immune reconstitution patient . - To evaluate impact prophylactic transfer donor CD4 cell upon non-relapse mortality overall survival patient . OUTLINE : This multicenter study . Patients receive fludarabine IV , melphalan IV , alemtuzumab IV reduce intensity condition T-cell depletion follow reduced-intensity HLA-identical sibling stem cell transplantation day 0 . Withdrawal cyclosporine immunosuppression therapy commence day 40 taper period 3-4 week , accord discretion PI . Patients reassess day 70-90 post-transplantation . Patients stable engraftment , significant graft-versus-host disease , early relapse progression randomize 1 2 treatment arm . - Arm I : Patients receive allogeneic CD4 donor lymphocyte infusion ( DLI ) dose 1 x10^6 CD4 cells/kg body weight without medication day 100-120 . - Arm II : Patients receive treatment . Patients undergo blood sample collection chimerism study translational research . After completion study treatment , patient follow periodically 1 year annually . Peer Reviewed Funded Endorsed Leukaemia &amp; Lymphoma Research ( LLR )</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>At registration ( pretransplant ) Haematological cancer ONE OF following : NonHodgkin 's lymphoma ( NHL ) CR PR Hodgkin 's lymphoma ( HL ) CR PR Chronic ( Pro ) lymphocytic leukaemia ( CLL/PLL ) CR PR Plasma cell myeloma ( PCM ) CR , VGPR PR Acute myeloid leukaemia ( AML ) CR Acute lymphoblastic leukaemia ( ALL ) CR Myelodysplastic syndrome ( MDS ) &lt; 10 % blast bone marrow Chronic myelomonocytic leukaemia ( CMML ) &lt; 10 % blast bone marrow Have undergone disease reassessment within 8 week prior registration HLAidentical sibling transplant perform use one follow reduce intensity alemtuzumabcontaining condition regimen : Fludarabinebusulphanalemtuzumab Fludarabinemelphalanalemtuzumab BCNUetoposidecytarabinemelphalan ( BEAM ) alemtuzumab CCNUetoposidecytarabinemelphalan ( LEAM ) alemtuzumab Aged ≥18 year , &lt; 70 year Written inform consent Exclusion Criteria Women pregnant breastfeed Life expectancy &lt; 8 week Currently take part interventional clinical research study ( involve IMP , ATMP cellular therapy ) Organ dysfunction : Creatinine &gt; 200μmol/l , Bilirubin &gt; 50μmol/l , AST/ALT &gt; 3x ULN Posttransplant Active acute GvHD Prior grade IIIV GvHD Relapse progressive disease Primary secondary graft failure Other cellular therapy Requirement ongoing immunosuppression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>Non-Hodgkin 's lymphoma</keyword>
	<keyword>Hodgkin 's lymphoma</keyword>
	<keyword>Chronic ( Pro- ) lymphocytic leukaemia</keyword>
	<keyword>Plasma cell myeloma</keyword>
	<keyword>Acute myeloid leukaemia</keyword>
	<keyword>Acute lymphoblastic leukaemia</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>Chronic myelomonocytic leukaemia</keyword>
</DOC>